Following the approval of the Ethics Committee for the Experimental Digital Autonomous Respiratory Rehabilitation Physiotherapy Trial, the joint trial of Biogradient and SHEBA Tel Hashomer medical center in Israel is expected to begin.
As part of the company's development model, the algorithm's efficiency and safety phase is to be demonstrated in the clinical trial. The experiment will test the ability of the algorithm to enhance rehabilitation of COVID19 and COPD patients.
Rehabilitation efficiency is measured by shortening the rehabilitation time and maximizing personal rehabilitation potential.
BioGradient, a company that specializes in developing algorithms to maximize personalized physiological capabilities, views the experiment as the final step before releasing the algorithm for use.
Our market is composed of software companies, those in the smartwatch industry and broad market makers looking to focus on improving physiological metrics.
The company expects to release the algorithm to the market within five months and be a key part of the world's response to the rehabilitation challenge of COVID19 patients.
